Biotech Stocks Facing FDA Decision In February 2022

In January, 2 novel drugs received the regulatory nod in the U.S., and they are Swiss biotech Idorsia Ltd.'s Quviviq to treat insomnia and Pfizer's Cibinqo to treat refractory, moderate-to-severe atopic dermatitis. Now, let's take a look at the biotech stocks facing FDA decision in February.

from RTT - Top Story https://ift.tt/3GUP3Jn
via IFTTT